EVALUATION OF THE PERFORMANCE OF MASEF SCORE IN PATIENTS WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) UNDER A LIPID-LOWERING MEDICATION

被引：0
|
作者：
Martinez-Arranz, Ibon [1 ]
Banales, Jesus [2 ]
Alonso, Cristina [1 ]
Mayo, Rebeca [1 ]
Arrese, Marco [3 ]
Crespo, Javier [4 ]
Noureddin, Mazen [5 ]
机构：
[1] OWL Metabol, Derio, Spain
[2] Univ Basque Country, Donostia Univ Hosp, Biodonostia Res Inst, Leioa, Spain
[3] Pontificia Univ Catolica Chile, Santiago, Chile
[4] Marques Valdecilla Univ Hosp, Univ Cantabria, IDIVAL, Santander, Spain
[5] Houston Methodist Hosp, Houston, TX USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
821
引用
收藏
页码：S619 / S620
页数：2
相关论文
共 50 条
  • [41] BRIDGING GAPS IN VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY (VCTE) USAGE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE/STEATOHEPATITIS (MASLD/MASH) PATIENTS: INSIGHTS ON SOCIODEMOGRAPHIC INFLUENCES AND CARE CONNECTIONS
    Das, Taranika Sarkar
    Udaikumar, Jahnavi
    Ho, Kimberly
    Wilson, Carolyn
    De Leon, Inna
    Gautam, Kripali
    Meng, Xucong
    Stromberg, Jennifer
    Sarwar, Raiya
    Kilaru, Saikiran
    Hameed, Bilal
    Shaukat, Aasma
    HEPATOLOGY, 2024, 80 : S717 - S718
  • [42] Body mass index (BMI) as a prelude to hepatocellular carcinoma (HCC) and metabolic dysfunction-associated steatohepatitis (MASH) risk factors in patients with no identified risk factor for developing hepatocellular carcinoma (HCC)
    Al Mahmasani, Layal
    Capanu, Marinela
    Srivastava, Amitabh
    Chou, Joanne F.
    Shia, Jinru
    El Dika, Imane H.
    Yaqubie, Amin
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] A PHASE II TRIAL OF FAZPILODEMAB (BFKB8488A), A FIBROBLAST GROWTH FACTOR RECEPTOR 1C/KLOTHO. AGONIST, IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
    Harrison, Stephen A.
    Zou, Yixuan
    Zhang, Lu
    Dash, Ajit
    Garchitorena, Abigail
    Fredrickson, Jill
    Gutierrez, Johnny
    Yoshida, Kenta
    Liu, Yanqiu
    Kunder, Rebecca
    Wilson, Maria
    Wong, Chin
    HEPATOLOGY, 2024, 79 (02) : E47 - E48
  • [44] GLP-1'S ROLE IN LOWERING HCC RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS AND TYPE 2 DIABETES - A MULTICENTER PROPENSITY-MATCHED STUDY
    Sohail, Abdullah
    Aslam, Aysha
    Brown, Kyle
    HEPATOLOGY, 2024, 80 : S844 - S845
  • [45] Characteristics and risk of major adverse liver outcomes and major cardiovascular events among swedish patients with diagnosed and high risk of metabolic dysfunction-associated steatohepatitis-a REVEAL-MASH study
    Grip, Emilie Toresson
    Apecechea, Nikolas Scheffer
    Basuroy, Ron
    Johansen, Pierre
    Mangla, Kamal Kant
    Skroder, Helena
    Hagstrom, Hannes
    JOURNAL OF HEPATOLOGY, 2024, 80 : S37 - S37
  • [46] Assessments of health utilities in patients with metabolic dysfunction-associated steatohepatitis (MASH): cross-walk between CLDQ-NASH, SF-6D, and the EuroQol EQ-5D
    Younossi, Zobair
    Stepanova, Maria
    Fishman, Jesse
    Dodge, James
    Labriola, Dominic
    Taub, Rebecca
    Nader, Fatema
    JOURNAL OF HEPATOLOGY, 2024, 80 : S652 - S652
  • [47] Age, Abdominal Obesity, and Baseline hsCRP Are Associated with LDL-C, Non-HDL-C and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High CHD Risk
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Hsueh, Willa A.
    Rosen, Jeffrey B.
    Lin, Jianxin
    Shah, Arvind K.
    Tomassini, Joanne E.
    Lowe, Robert S.
    Tershakovec, Andrew M.
    DIABETES, 2011, 60 : A188 - A188
  • [48] Sequential approach using combination of newly developed HOMA2-IR-ALT-TE-MASH (HALT-M) score and magnetic resonance elastography for non-invasive identifying at-risk metabolic dysfunction-associated steatohepatitis in obese subjects
    Shin, Seung Kak
    Lee, Yoonseok
    Kwon, Oh Sang
    Kim, Yun Soo
    Kim, Ju Hyun
    Lee, Dae Ho
    JOURNAL OF HEPATOLOGY, 2024, 80 : S542 - S543
  • [49] CLINICAL, BIOLOGICAL AND IMAGING PREDICTORS OF AT-RISK METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): COMBINED DATA FROM MULTIPLE THERAPEUTIC TRIALS INCLUDING MORE THAN 6,000 PATIENTS (IN COLLABORATION WITH NAIL-NIT CONSORTIUM)
    Harrison, Stephen A.
    Dubourg, Julie
    Alkhouri, Naim
    Noureddin, Mazen
    Schattenberg, Joern M.
    Jeannin, Sophie
    HEPATOLOGY, 2023, 78 : S249 - S253
  • [50] Diagnostic performance of new BAST score versus FIB-4 index in predicating of the liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
    Helal, Eman
    Elgebaly, Fatma
    Mousa, Nasser
    Elbaz, Sherif
    Abdelsalam, Mostafa
    Abdelkader, Eman
    El-Sehrawy, Amr
    El-wakeel, Niveen
    El-Emam, Ola
    Hashem, Manal
    Elmetwalli, Alaa
    Mansour, Shimaa
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01)
12345